US Bancorp DE Purchases 758 Shares of Glaukos Corporation $GKOS

US Bancorp DE boosted its holdings in Glaukos Corporation (NYSE:GKOS) by 12.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,752 shares of the medical instruments supplier’s stock after buying an additional 758 shares during the period. US Bancorp DE’s holdings in Glaukos were worth $697,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Maryland State Retirement & Pension System increased its holdings in Glaukos by 4.7% in the second quarter. Maryland State Retirement & Pension System now owns 16,793 shares of the medical instruments supplier’s stock valued at $1,735,000 after purchasing an additional 751 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Glaukos by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $2,758,000 after buying an additional 700 shares during the period. KLP Kapitalforvaltning AS boosted its position in Glaukos by 7.3% during the second quarter. KLP Kapitalforvaltning AS now owns 11,700 shares of the medical instruments supplier’s stock valued at $1,208,000 after purchasing an additional 800 shares during the last quarter. Truist Financial Corp boosted its position in Glaukos by 138.9% during the second quarter. Truist Financial Corp now owns 7,296 shares of the medical instruments supplier’s stock valued at $754,000 after purchasing an additional 4,242 shares during the last quarter. Finally, Park Place Capital Corp lifted its position in shares of Glaukos by 68.4% in the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 162 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. William Blair upgraded Glaukos to a “strong-buy” rating in a research note on Thursday, July 31st. Citigroup reduced their target price on Glaukos from $140.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Mizuho set a $130.00 target price on Glaukos in a report on Thursday, July 31st. UBS Group raised their price objective on Glaukos from $125.00 to $134.00 and gave the company a “buy” rating in a report on Thursday, July 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $116.92.

Glaukos Price Performance

GKOS stock opened at $87.49 on Friday. The company has a market capitalization of $5.02 billion, a P/E ratio of -53.02 and a beta of 0.76. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a 52-week low of $77.10 and a 52-week high of $163.71. The business has a 50-day simple moving average of $87.74 and a two-hundred day simple moving average of $92.17.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company’s quarterly revenue was up 29.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. Research analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.